Elidel Related Published Studies
Well-designed clinical trials related to Elidel (Pimecrolimus)
Pimecrolimus cream 1% in erosive oral lichen planus--a prospective randomized double-blind vehicle-controlled study. [2008.09]
Pimecrolimus cream 1% in erosive oral lichen planus- a prospective randomized double-blind vehicle-controlled study. [2008.07.19]
A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. [2008.07]
The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: A double-blind, placebo-controlled clinical trial. [2008.06.16]
A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea. [2008.06]
Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. [2008.05]
Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis. [2008.05]
Anti-inflammatory effect of pimecrolimus in the sodium lauryl sulphate test. [2008.04]
Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. [2008.03.13]
A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea. [2008.03.03]
Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study. [2008]
A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. [2007.11]
Skin reactions to pimecrolimus cream 1% in patients allergic to propylene glycol: a double-blind randomized study. [2007.09]
Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. [2007.08]
Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. [2007.08]
Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. [2007.07.19]
Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. [2007.04]
Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%. [2007.01]
Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. [2007]
Pimecrolimus 1% cream in non-specific inflammatory recurrent balanitis. [2007]
Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. [2006.12.21]
1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. [2006.09]
Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis. [2006]
Modulation of atopy patch test and skin prick test by pretreatment with 1% pimecrolimus cream. [2006]
Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age. [2006]
Pimecrolimus and narrowband UVB as monotherapy or combination therapy in children and adolescents with atopic dermatitis. [2006]
A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis. [2005.08]
Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. [2005.06]
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. [2005.06]
Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. [2005.06]
The effectiveness of 1% pimecrolimus cream in the treatment of oral erosive lichen planus. [2005.04]
Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. [2005.02]
Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome. [2005.01]
Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. [2004.12]
Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. [2004.11]
Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. [2004.11]
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. [2004.11]
Pimecrolimus for the treatment of vulvar lichen sclerosus: a report of 4 cases. [2004.10]
A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. [2004.10]
Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. [2004.06]
Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. [2004.01]
Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. [2004.01]
Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis. [2004]
Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. [2004]
Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. [2003.02]
An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. [2003]
Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple oral administration. [2003]
The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis. [2002.12]
Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. [2002.10]
Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. [2002.08]
Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. [2002.07]
Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. [2002.04]
Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. [2002]
Well-designed clinical trials possibly related to Elidel (Pimecrolimus)
Emerging therapeutic targets in psoriasis. [2004.06]
SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. [2001.04]
The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. [2001.03]
The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. [1998.12]
Other research related to Elidel (Pimecrolimus)
An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. [2008.08.01]
Lichen striatus in adults and pimecrolimus: open, off-label clinical study. [2008.07]
Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis. [2008.06.24]
Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease. [2008.06]
A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. [2008.05.05]
Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial. [2008.05]
Pimecrolimus 1% cream for pruritus in postmenopausal diabetic women with vulvar lichen simplex chronicus: A prospective non-controlled case series. [2008.04.11]
Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. [2008.04]
Ethanol-induced flushing with topical pimecrolimus use. [2008.03]
Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease. [2008.02.26]
Two cases of Zoon's balanitis treated with pimecrolimus 1% cream. [2008.02]
Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study. [2008.02]
Use of pimecrolimus cream in disorders other than atopic dermatitis. [2008.01]
Pimecrolimus: skin disposition after topical administration in minipigs in vivo and in human skin in vitro. [2008.01]
Acute actinic cheilitis-like chemical irritant reaction following accidental contact with ethylene glycol-favorable response to topical 1% pimecrolimus cream: a case report. [2008]
Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. [2007.12.20]
Anti-inflammatory effect of pimecrolimus in the sodium lauryl sulphate test. [2007.11.19]
Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus. [2007.11]
Topical pimecrolimus does not prolong clear graft survival in a rat keratoplasty model. [2007.11]
Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: A comparison with cyclosporine A. [2007.10.18]
Topical pimecrolimus for eczema. [2007.10.17]
Pimecrolimus cream (1%) efficacy in perioral dermatitis - results of a randomized, double-blind, vehicle-controlled study in 40 patients. [2007.10]
Efficacy and safety of pimecrolimus-eluting stents in porcine coronary arteries. [2007.10]
Safety and efficacy of pimecrolimus cream 1% in the daily practice: results of a patient self-observation study in patients with atopic dermatitis. [2007.10]
Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: an open-label clinical study in Korean patients. [2007.10]
Molluscum contagiosum infection associated with pimecrolimus use in pityriasis alba. [2007.09]
Two therapeutic challenges: periocular and genital vitiligo in children successfully treated with pimecrolimus cream. [2007.09]
Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus. [2007.07.19]
Pimecrolimus versus topical corticosteroids in dermatology. [2007.07]
An exploratory study to evaluate the efficacy of pimecrolimus cream 1% for the treatment of pityriasis alba. [2007.07]
The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update. [2007.06]
[Topical pimecrolimus and tacrolimus and the risk of cancer] [2007.06]
Pimecrolimus 1 percent cream and pulsed dye laser in treatment of a patient with reticular erythematous mucinosis syndrome. [2007.05.01]
Pimecrolimus 1% cream in the treatment of vulvar lichen sclerosus in postmenopausal women. [2007.05]
An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV. [2007.05]
Retrospective analysis of pimecrolimus cream 1% for treatment of facial vitiligo. [2007.05]
Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus. [2007.05]
Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. [2007.04]
An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption. [2007.04]
Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis. [2007.04]
Treatment of pityriasis rubra pilaris with pimecrolimus cream 1%. [2007.03]
Netherton syndrome: successful use of topical tacrolimus and pimecrolimus in four siblings. [2007.03]
Allergic contact dermatitis from pimecrolimus in a patient with tacrolimus allergy. [2007.02]
Pimecrolimus cream 1% is effective in asteatotic eczema: results of a randomized, double-blind, vehicle-controlled study in 40 patients. [2007.01]
|
